2460. Factors Associated With Uptake of Meningococcus B Vaccination After an ACIP Category B Recommendation

BACKGROUND: Two meningococcal vaccines (MenB) were licensed for 10–25 year olds in 2015 and given a Category B recommendation with a preferred window of 16–18 years old without high-risk comorbidity. Little is known about uptake of MenB after a Category B recommendation. METHODS: We conducted a retrospective cohort study of 16–23 year olds presenting to 31 primary care sites in a pediatric care network October 23, 2015–April 30, 2017. Using pivot tables and chi square analysis, we examined EHR data for associations between MenB receipt and patient/provider demographics (patient age, sex, race, insurance; provider years in practice), vaccinations, care site (urban vs. suburban), and high-risk comorbidity (asplenia, sickle cell, complement deficiency). RESULTS: Of 45,428 patients, 51% were female, 68% were 16–18 years old, and 21% received ≥1 MenB. 43% of those patients completed the 2-dose series. Rates of MenACWY booster receipt (32%) exceeded MenB, and 28% received both vaccines. A higher proportion of patients with ≥1 MenB were Asian, older, and privately insured (Table 1). More privately insured patients completed the series (48% vs. 26% Medicaid, P < 0.001). 22% of high-risk patients received MenB, similar to their peers. MenB receipt increased with provider years in practice but declined in those practicing >30 years (Table 1). MenB initiation varied widely between sites (1–45%). CONCLUSION: MenB uptake in this cohort was low. Variation by site, provider years in practice, and potential sociodemographic disparity suggests that advice and acceptance in the setting of a Category B recommendation is not uniform. Further study is needed to clarify how these factors influence MenB receipt in teens. DISCLOSURES: All authors: No reported disclosures.